Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-25. ← Back to Evidence Library
Gonadorelin: what the evidence says
At a glance
Gonadorelin is natural GnRH made in a lab. It was sold in the US as Factrel (a diagnostic test drug); current US availability: UNVERIFIED, not checked against FDA. It is still used in some countries for pituitary testing and pump treatment. R1, R2
What it is: the same 10-amino-acid hormone the brain uses to tell the pituitary to release LH and FSH. It lasts only minutes, so treatment uses a pump that gives pulses. R1
What the evidence says: small studies in men with congenital hypogonadotropic hypogonadism (a condition where the brain does not send the GnRH signal) show sperm production returns with pump treatment. No trials found for the gray-market use alongside steroids or TRT to "keep the testes working". R1
Biggest risks: rare severe allergic reactions (anaphylaxis) have been reported. R2
Rating
| Human Human (pulsatile pump treatment for congenital hypogonadotropic hypogonadism) | Limited: one small nonrandomized study of 28 men (10 pump vs 18 hCG/hMG) R1; historical FDA diagnostic/pump products (Factrel NDA 018123, Lutrepulse) discontinued R4 |
| Human Human (gray-market injections alongside steroids/TRT or for PCT) | No human data: no trials found |
| Regulatory | Historical FDA approvals discontinued (Factrel NDA 018123, Lutrepulse; openFDA Oct 24, 2026) R4 · Not approved for TRT testicular maintenance · WADA 2026: prohibited at all times in males (S2.2.1, named) R3 |
| Established human dose | None for gray-market use. Study arms are in Study details |
Evidence verdict: Human (CHH pump): Limited · Human (gray-market): No human data Card verdict: Limited (pump treatment for congenital hypogonadotropic hypogonadism) · Bodybuilding/PCT use: No human data Card note: Varies by use, see page
This page reports what studies used. It is not dosing advice.
Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source
What is it?
Gonadorelin is identical to natural gonadotropin-releasing hormone (GnRH). Because it is broken down within minutes, it works only as frequent pulses; continuous long-acting cousins such as triptorelin do the opposite and shut the system down (see Triptorelin). R1
Does it work?
- Human Men with congenital hypogonadotropic hypogonadism: in a nonrandomized study, sperm appeared earlier with a gonadorelin pulse pump than with hCG/hMG injections (median 6 vs 14 months); final rates were similar (90% vs 83.3%). R1
- Unknown Gray-market use: claims that intermittent injections keep the testes active during TRT or steroid cycles are anecdotal. Natural GnRH needs pulses every hour or two to work, which a few injections do not mimic. R1
Is it safe?
- Caution Skin reactions at the pump site were common in the pump study. R1
- Caution A case report describes anaphylaxis with seizures in a girl given gonadorelin for a pituitary test. R2
Gray-market "research use only" Gonadorelin: extra risks
Unknown contents. Products sold online as "research use only" or "not for human use" are not made under drug-quality rules, so identity, strength and sterility are unknown. This is a general caution; we have not found testing data for this product specifically. Unknown
What we don't know
- Unknown Whether gray-market injection patterns do anything for testicular function
- Unknown Current US regulatory and compounding status
Is it legal?
US FDA: Historical branded gonadorelin products (Factrel, gonadorelin hydrochloride NDA 018123, and Lutrepulse, gonadorelin acetate) are listed as Discontinued in Drugs@FDA (openFDA query, Oct 24, 2026). R4 Gonadorelin is not approved for TRT testicular maintenance or post-cycle therapy. EU, UK, Japan, China: UNVERIFIED not checked against EMA, MHRA, PMDA or NMPA. WADA: prohibited at all times (in and out of competition) in males under S2.2.1, "testosterone-stimulating peptides in males", which names gonadorelin (GnRH); S2 substances are non-Specified R3.
Study details
These are doses researchers used, not recommendations.
R1 Human Human: Pulsatile gonadorelin pump vs gonadotropins (Zhang 2019)
Nonrandomized; ChiCTR-OPC-16009168.
| Study | People / model | Route | Dose used | Follow-up | Reported | Side effects / dropouts | Citation |
|---|---|---|---|---|---|---|---|
| Zhang 2019 | 10 pump, 18 hCG/hMG; azoospermic men with CHH | Subcutaneous pump (pulsed) | Pulsatile gonadorelin; amounts not in abstract | 24 months | Sperm onset median 6 vs 14 months; sperm in 90% vs 83.3% | Pump-site skin reactions common | PMID 30569789 |
R2 Human Human: Anaphylaxis case report (Akın 2015)
| Study | People / model | Route | Dose used | Follow-up | Reported | Side effects / dropouts | Citation |
|---|---|---|---|---|---|---|---|
| Akın 2015 | 1 girl, age 8 | Intravenous (diagnostic test) | Not in abstract | Minutes | — | Anaphylaxis with loss of consciousness and seizures; recovered | PMID 26197466 |
Full reference list (PubMed entries verified Oct 24, 2026)
- R1 Zhang L, et al. Am J Mens Health. 2019;13(1):1557988318818280. PMID 30569789
- R2 Akın O, et al. J Pediatr Endocrinol Metab. 2015;28(11-12):1387-9. PMID 26197466
- R3 WADA. World Anti-Doping Code International Standard: Prohibited List 2026 (in force Jan 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (text read Oct 24, 2026)
- R4 US FDA. Drugs@FDA record for Factrel (gonadorelin hydrochloride, NDA 018123; status: Discontinued), queried via openFDA Oct 24, 2026. https://www.accessdata.fda.gov/scripts/cder/daf/
Disclaimer
This page summarizes published research for education and harm reduction; it is not medical advice or a recommendation to use Gonadorelin. Talk to a clinician you trust before using any drug, and report side effects to FDA MedWatch.
Approved for Adam Greene by Dr. Nova Reyes, 2026-10-25.